Infectious Diseases & Travel Medicine & Family Medicine
Typhoid Fever | Omicron Clinic Quebec
Typhoid fever is a systemic bacterial infection caused by Salmonella enterica serovar Typhi (commonly known as Salmonella Typhi), a Gram-negative bacterium of the Enterobacteriaceae family, which is strictly human in its reservoir. Paratyphoid fever, which is clinically similar but generally less severe, is caused by Salmonella Paratyphi A, B, or C. Together, they constitute enteric fevers—the term preferred by the WHO, which encompasses both conditions. Transmission is fecal-oral, through ingestion of water or food contaminated by the feces of infected individuals or chronic asymptomatic carriers. Typhoid fever remains a major public health problem in regions of the world with limited access to safe drinking water and sanitation, with a global incidence estimated at 11 to 21 million cases annually and 128,000 to 161,000 deaths per year according to the WHO—primarily in South Asia (India, Pakistan, Bangladesh — >70% of the global burden), Southeast Asia, sub-Saharan Africa, and Latin America. In Canada, virtually all cases are imported—travelers returning from endemic areas or recent immigrants—with approximately 80 to 150 cases reported annually. The pathophysiology is remarkable: after ingestion, Salmonella Typhi penetrates the ileal mucosa via M cells in Peyer’s patches, invades submucosal macrophages, and spreads via the lymphatic and bloodstream to the liver, spleen, the bone marrow, and the gallbladder, where it can persist indefinitely by forming an intracellular reservoir protected from antibiotics and the immune system—the basis of chronic carriage. The global emergence of multidrug-resistant (MDR) strains—resistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole—and extensively drug-resistant (XDR) strains—which are additionally resistant to fluoroquinolones and third-generation cephalosporins, notably the H58 strain in Pakistan—constitutes a major therapeutic threat, making preventive vaccination all the more strategic.
Clinical presentation, diagnosis, and complications
- Clinical presentation by weeks: incubation: 7 to 21 days (average 10-14 days) after ingestion - infectious dose: 10⁵ to 10⁹ bacteria (highly contaminated water or food); week 1 : gradual onset - rising plateau fever (39-40°C) + intense headache + general malaise + anorexia + diffuse abdominal pain + constipation (often, contrary to popular belief - diarrhea is more common in young children) + non-productive dry cough (10-20 %) + relative bradycardia (dissociated pulse - low heart rate despite high fever - Faget's sign); week 2: plateau fever (permanent 39-40°C) + tuphos (altered consciousness, prostration, profound depression) + typhoid roseola (pinkish macules 2-4 mm, erasable with pressure, on the trunk - visible in 30-50 % of cases - fleeting, difficult to see on dark skin) + splenomegaly (50-70 %) + hepatomegaly + gurgling of the right iliac fossa (Piorry's sign) + sabral tongue (coated) ; week 3: maximum risk of complications - progressive improvement in the absence of complications + «mashed pea» diarrhea possible (greenish liquid stools - 30-50 %); week 4 and beyond: progressive defervescence - cure without antibiotic therapy in 4-6 weeks in surviving immunocompetent patients - relapse in 5-10 % of cases (especially under short treatment)
- Feared complications: intestinal bleeding (2–5% of untreated cases): melena or rectal bleeding — results from ulceration of Peyer’s patches — occurs in the third week — conservative medical treatment (transfusion + NPO) in most cases; intestinal perforation (1–3% of untreated cases): the most lethal complication — peritonitis due to ileal perforation in the third week — sudden abdominal pain + guarding or rigidity + pneumoperitoneum (subdiaphragmatic air crescent on upright chest X-ray) → emergency laparotomy + broad-spectrum antibiotic therapy + resuscitation — surgical mortality 10–40% of untreated cases; typhoid encephalopathy (1–5% of cases): confusion + agitation + meningeal signs + seizures — combination with IV dexamethasone (Hoffman 1984 randomized trial, NEJM — mortality reduced from 55% to 10% in severe cases); typhoid myocarditis: ECG abnormalities (QT prolongation + ST-T changes) — rare arrhythmic complications; chronic asymptomatic carriage (>1 year after infection, bacteria in bile and the gallbladder): 1–6% of adults — risk of prolonged transmission to contacts + association with gallbladder carcinoma (long-term) — eradication treatment essential for food handlers and healthcare workers
- Biological diagnosis: blood cultures: gold standard - positive in 60-80 % of untreated cases at 1st week (before antibiotic therapy) - yield reduced if prior antibiotic therapy or late sampling - 2 to 3 pairs at 1h intervals before first dose of antibiotics; myelocultures : positivity 90-95 % - more sensitive than blood culture + less affected by prior antibiotic therapy - performed in specialized hospital setting if blood cultures negative and strong suspicion; coprocultures: positive in 3rd-4th week (fecal excretion) - useful for chronic carriage; Widal serology (anti-Salmonella O and H agglutinins): historical test - low sensitivity (60 %) + low specificity (cross-reactivity with other Salmonella + previous vaccinations + inflammatory diseases) - NOT recommended in 2024 as main diagnostic tool - persistence in some resource-limited countries; blood/stool PCR: available in reference laboratories (NML - National Microbiology Laboratory in Winnipeg) - sensitivity 60-75 % - useful if blood cultures negative; CBC: leukopenia (characteristic - 2,000-4,000/µL) + absence of eosinophils + moderate anemia + mild thrombocytopenia; liver workup: moderate elevation of transaminases (× 2-3 N); CRP moderately elevated; mandatory reporting: MADO in Quebec (Public Health Department) + PHAC
Treatment and prevention
| Treatment / Prevention | Molecules, diagrams, and modalities | Effectiveness, resistances, and precautions |
|---|---|---|
| Antibiotic therapy — uncomplicated forms Fluoroquinolones or cephalosporins depending on sensitivity |
The choice of antibiotic therapy depends on the strain’s resistance profile (antibiogram) and the region of origin of the case—resistance patterns vary considerably by geography; first-line treatment if the strain is susceptible to fluoroquinolones: ciprofloxacin 500 mg PO twice daily for 7–10 days (adults) — or levofloxacin 500 mg once daily for 7 days — excellent intracellular penetration + good oral bioavailability — cure rate >95% for susceptible strains — DO NOT use if ciprofloxacin MIC ≥0.125 µg/mL (intermediate resistance common in South Asia); first-line treatment if resistance to fluoroquinolones (MDR or XDR strains — South Asia +++): cefixime PO 400 mg × 2/day × 14 days (oral third-generation cephalosporin) — or ceftriaxone IV/IM 2 g × 1/day × 10–14 days (if severe or oral administration not possible); azithromycin 1 g PO on Day 1 followed by 500 mg × 4 days (total 5 days): effective for MDR strains (non-XDR) — excellent intracellular penetration (high intraphagocytic concentration) — advantage: oral route + low resistance rates currently in Southeast Asia and Africa — increasingly recommended as first-line outpatient treatment for non-XDR MDR strains (WHO 2018); treatment of XDR strains (Pakistan — H58 XDR): carbapenems (meropenem 1 g IV × 3/day × 10–14 days) — first-line for XDR + some XDR strains susceptible to azithromycin — ceftazidime-avibactam if resistance to carbapenems (rare) | Resistance profile by region of origin — a practical guide for Quebec clinicians: India, Pakistan, Bangladesh, Nepal, Sri Lanka: high prevalence of MDR strains + intermediate resistance to fluoroquinolones (MIC ≥0.125) + XDR strains in Pakistan — use azithromycin or IV ceftriaxone empirically while awaiting culture and sensitivity results; Sub-Saharan Africa: strains often still susceptible to fluoroquinolones but MDR on the rise; Latin America, Mexico: fluoroquinolones generally effective; Southeast Asia (Thailand, Vietnam, Cambodia): frequent intermediate resistance to fluoroquinolones — prefer azithromycin; importance of a complete susceptibility test (MIC for ciprofloxacin + sensitivity to azithromycin + third-generation cephalosporins) before any treatment adjustment; expected clinical response: resolution of fever within 3 to 7 days with appropriate treatment — no resolution of fever by days 5–7 → reevaluation (resistance + relapse + complication); minimum duration: 7 days (fluoroquinolones for susceptible strains) — 10–14 days (ceftriaxone or azithromycin) — shortening the course increases the risk of relapse (5–10 %) |
| Antibiotic Therapy - Severe Forms and Complications Ceftriaxone IV ± dexamethasone — hospitalization |
Indications for hospitalization and IV antibiotic therapy: persistent high fever >39.5 °C + altered mental status + vomiting preventing oral administration + significant splenomegaly + suspected complications (intestinal bleeding, perforation, myocarditis, encephalitis) + immunosuppression + pregnancy + children <2 years of age + XDR strain; IV ceftriaxone 2 g × 1/day: standard IV treatment for severe cases and MDR/XDR strains sensitive to C3G — duration 10–14 days — switch to oral cefixime 400 mg × 2/day upon clinical improvement (afebrile for >48 hours + able to eat) — total duration 14 days; IV meropenem 1 g × 3/day: treatment for C3G-resistant XDR strains — duration 14 days — reserve for documented C3G-resistant strains (antibiogram required); IV dexamethasone for severe cases with encephalopathy or septic shock: 3 mg/kg IV loading dose followed by 1 mg/kg × 8 times daily × 48 hours — Hoffman trial 1984 (NEJM) — reduction in mortality from 55% to 10% in very severe cases (impaired consciousness score + shock) — controversial outside of cases with severe sepsis (risk of increasing the frequency of relapses and carriers); intestinal perforation: emergency laparotomy + primary suture or ileal resection + peritoneal lavage + broad-spectrum antibiotic therapy covering anaerobes (piperacillin-tazobactam + metronidazole) + fluid resuscitation + PPIs; intestinal hemorrhage: conservative management (transfusion + NPO + nasogastric tube) → colonoscopy/angiography if active bleeding persists → hemostatic surgery if unsuccessful | Dexamethasone in severe typhoid fever remains one of the few interventions with demonstrated efficacy on mortality in a randomized controlled trial — it is recommended by the WHO for cases with altered consciousness or shock (WHO 2011 — guidelines for the treatment of typhoid fever); its use in moderate forms without stupor is not recommended (no demonstrated benefit + risk of masking signs of complication + possible increase in carriage); close monitoring during hospitalization: daily CBC (thrombocytopenia + leukopenia) + creatinine + liver function tests + ECG if myocarditis suspected + daily abdominal auscultation (disappearance of bowel sounds = early sign of perforation) + temperature × 4/day; control blood cultures at the end of treatment: not systematic if satisfactory clinical response — indicated if fever persists after 7 days of appropriate treatment or if relapse is suspected; mandatory reporting and epidemiological investigation: typhoid fever is a reportable infectious disease in Quebec — the DSP identifies food contacts and potential carriers in the case's social circle. |
| Chronic Portage — Eradication Prolonged Ciprofloxacin ± Cholecystectomy |
Chronic carriage of Salmonella Typhi: defined as the continued excretion of S. Typhi in feces or urine for more than 12 months after the acute phase — affects 1 to 6% of adult patients (more common in women, the elderly, and individuals with gallstones) — the gallbladder is the primary reservoir (intracellular bacteria in gallbladder epithelial cells and in gallstones — bacterial biofilm); Screening for carriage: 3 consecutive monthly stool cultures starting 3 months after recovery + blood cultures if recurrent fever — essential for food handlers, healthcare workers, and children attending daycare; eradication therapy for carriers: ciprofloxacin 750 mg PO × 2/day × 4 weeks: first-line treatment for carriers without gallstones — eradication rate 80–90% for strains sensitive to fluoroquinolones; ampicillin 1.5–2 g PO × 4/day × 6 weeks + probenecid 500 mg × 4/day: alternative if strain is susceptible (less commonly used currently); laparoscopic cholecystectomy: indicated if gallstones are present + antibiotic treatment failure — the presence of gallstones (bacterial biofilm) makes antibiotic eradication alone insufficient (failure rate 60–70% % with gallstones) — cholecystectomy + perioperative antibiotic therapy = eradication >90% %; fluoroquinolone resistance in carriers: azithromycin 500 mg × 1/day × 28 days — limited data but efficacy reported in case series | Chronic carriage is a public health priority—an asymptomatic carrier can infect dozens of people through water or food over the course of years (see «Typhoid Mary»—Mary Mallon, a cook in New York in the early 20th century who was a chronic carrier of S. Typhi—linked to 51 documented cases and 3 deaths); in Quebec, exclusion from work (food service, restaurants, healthcare, daycare) is mandatory for documented carriers until three negative stool cultures are confirmed following treatment—coordination with the regional Public Health Department (DSP); post-eradication treatment follow-up: 3 consecutive negative monthly stool cultures = cure of carriage → lifting of occupational exclusion; in chronic carrier patients with cholelithiasis, cholecystectomy is curative in >90% of cases and should be routinely offered — indefinite postponement of surgery maintains an active bacterial reservoir and a risk of community transmission |
| Typhoid fever vaccination Two vaccines available in Canada — recommended before travel |
Two typhoid vaccines are available in Canada and Quebec: injectable Vi polysaccharide vaccine (Typhim Vi — Typherix): S. Typhi Vi capsular polysaccharide antigen — single dose SC or IM — immunity within 2 weeks — booster every 3 years — efficacy: 60–80% % against clinical typhoid fever in endemic areas — well tolerated — can be administered as early as age 2 — covered by several travel insurance plans in Quebec; live attenuated oral vaccine (Vivotif — Ty21a strain): 4 enteric-coated capsules to be taken every other day (D1-D3-D5-D7) on an empty stomach + 1 hour before meals + store in the refrigerator — immunity within 7–10 days — booster every 7 years — efficacy: 60–70% % — from age 6 — contraindications: immunosuppression + concomitant antibiotics (3-day interval) + antimalarials (mefloquine + proguanil — interactions) + pregnancy (live vaccine); Vi-TT conjugate vaccine (Typbar TCV — Bharat Biotech): conjugate vaccine (Vi polysaccharide coupled with tetanus toxoid) — T-cell-mediated immunity + longer duration (5–10 years) + effective from 6 months of age + better efficacy against MDR strains — approved by the WHO (2018) + recommended in endemic countries — availability in Canada: not yet approved by Health Canada (2024) but accessible via importation for certain programs; indications for typhoid vaccination in Quebec: any traveler going to a moderate- or high-risk endemic area (South Asia — India, Pakistan, Bangladesh, Nepal — Southeast Asia, sub-Saharan Africa, Latin America) + household contacts of chronic carriers + laboratory technicians handling S. Typhi + VFR travelers (visiting friends and relatives — immigrants visiting their country of origin — risk often underestimated) | Efficacy of vaccines available in Canada (Typhim Vi and Vivotif): 60–80% % — significant but not absolute partial protection — vaccinated travelers must continue to follow food safety precautions (the «4C» rule: cook it, peel it, boil it, or forget it); minimum vaccination interval before departure: Typhim Vi — at least 2 weeks before departure; Oral Vivotif — at least 1 week (Day 7 after the last capsule = Day 7 after Day 7 = ideally 2 weeks) → consult the travel health clinic at least 4 to 6 weeks before departure for all necessary vaccinations and antimalarial prophylaxis; VFR (Visiting Friends and Relatives) travelers: account for 50–60% of typhoid fever cases imported into Canada — often unvaccinated (false sense of protection due to partial natural immunity from childhood + lack of awareness of the risk + absence of pre-travel medical consultation) — actively target this population for vaccination + dietary advice; vaccination recommended but not mandatory: unlike yellow fever, no country requires a typhoid vaccination certificate for entry — vaccination is a medical recommendation and not a legal requirement |
| Food prevention and water hygiene Water + food — fundamental measures when traveling |
Food and water safety measures are a complementary pillar to vaccination—they apply to all fecal-oral diseases (typhoid, cholera, hepatitis A, amoebic dysentery, shigellosis); safe drinking water: commercially bottled water with a sealed cap (check the cap is intact) + water boiled for 1 minute at a rolling boil (kills S. Typhi) + water treated with a ceramic or membrane filter + chlorination (clear water: 2 drops of sodium hypochlorite 5%/liter — wait 30 min) + Micropur tablets (chlorine dioxide — effective against bacteria and protozoa); avoid: ice cubes (water of unknown origin) + tap water + fresh juices made with tap water + unpasteurized milk + unpasteurized yogurt; safe foods: well-cooked foods + served hot (≥70 °C) + fruits and vegetables peeled by the traveler themselves + industrially packaged foods; high-risk foods: raw vegetables (salads, tomatoes, cucumbers) + sauces and condiments left at room temperature + raw or undercooked seafood and fish + buffets at room temperature + foods purchased from street vendors (although they often prepare food on demand and over heat); hand hygiene: wash with soap for 20 seconds + clean water before meals and after using the restroom — or hand sanitizer if soap is unavailable (effectiveness against S. Typhi: good for vegetative forms) | The «4Cs» rule remains valid and universally applicable when traveling in resource-limited areas: «Cook it, Peel it, Boil it or Forget it»; typhoid fever can be contracted in seemingly clean and reputable restaurants — contamination often comes from an asymptomatic chronic carrier cook or server handling food without adequate hand hygiene (hand-to-food contamination rather than waterborne in many urban settings); resources for Quebec travelers: TRAVEL.GC.CA (health advice by destination) + CANVAX application (PHAC) + travel health clinic websites + Canadian Immunization Guide (Public Health Agency of Canada — 2023 edition); food safety during special events in endemic countries (weddings, ceremonies): particularly high risk (large quantities of food prepared in advance + prolonged maintenance at room temperature) — report this type of event to your travel doctor before departure. |
ℹ️
XDR Typhoid Fever in Pakistan - An Emerging Threat Since 2016, Pakistan has been facing an epidemic of typhoid fever caused by the H58 XDR (extensively drug-resistant) strain - resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, fluoroquinolones and 3rd-generation cephalosporins. Only carbapenems (meropenem) and azithromycin remain active on the majority of Pakistani XDR strains. Cases of imported XDR typhoid fever have been documented in Canada, the United States, the United Kingdom and Australia among travellers or recent immigrants. Any traveler returning from Pakistan (or India, Bangladesh, Nepal) with confirmed typhoid fever should have a full antibiogram - empirical treatment with ciprofloxacin alone is insufficient and potentially dangerous. Azithromycin per os remains an effective option for XDR strains not resistant to azithromycin, but azithromycin resistance is also beginning to emerge in some Pakistani strains - underlining the urgency of wider access to the Typbar TCV conjugate vaccine in Pakistan and other high-prevalence countries.
Emergency – Fever + sudden abdominal pain upon return from travel
Consult immediately to the emergency room If you return from an endemic area (South Asia, Africa, Latin America) and present: persistent fever >5 days + sudden abdominal pain with guarding Typhoid intestinal perforation - urgent laparotomy.
High fever + altered consciousness + prostration Upon return from travel → typhoid fever with typhus or severe malaria — medical emergency — blood cultures + malaria smear as an emergency.
Any traveler with a fever returning from a tropical zone should mention recent travel to medical personnel — malaria and typhoid fever can be fatal if diagnosis is delayed.
Consult at Clinique Omicron
Clinique Omicron physicians offer travel medicine consultations, including typhoid fever vaccination (Typhim Vi or Vivotif), personalized dietary and hydration advice based on destination, and post-travel fever assessment. For confirmed cases of typhoid fever, physicians prescribe appropriate antibiotic treatment, coordinate mandatory reporting to the Public Health Department (DSP), and provide follow-up until documented eradication. Consultations are available at multiple service points in Quebec and via telemedicine. To make an appointment, visit cliniqueomicron.ca.
The content of this page is for informational purposes only and does not replace the advice of a qualified travel medicine professional. Any fever when returning from a tropical country requires urgent medical consultation—never self-treat.
Omicron Clinic
Need to consult a doctor?
Treatment within 24-48 hours. In-clinic or telemedicine, anywhere in Quebec.
Insurance receipts. 7j/7. No family doctor required.